Investor Overview

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer.

OUR MOLECULES

domvanalimab

domvanalimab

An Fc-silent anti-TIGIT antibody in Phase 2 and Phase 3 studies in non-small cell lung cancer in combination with zimberelimab and etrumadenant.

Learn More arrow

etrumadenant

etrumadenant

A dual adenosine A2a/A2b receptor agonist being evaluated in Phase 1 and Phase 2 studies across multiple indications, including lung, colon and prostate cancer.

Learn More arrow

quemliclustat

quemliclustat

A small molecule CD73 inhibitor in a randomized Phase 1 study for the treatment of metastatic pancreatic ductal adenocarcinoma.

Learn More arrow

zimberelimab

zimberelimab

An anti-PD1 monoclonal antibody being studied in various combinations across the portfolio, including a Phase 3 study to support the potential approvals of both zimberelimab and zimberelimab plus domvanalimab.

Learn More arrow

AB521

AB521

A HIF-2alfa inhibitor currently in a Phase 1 study.

Learn More arrow

OUR PARTNERSHIPS

Partnerships and collaborations enable our ability to accelerate the global investigation of novel combination treatments that address major unmet needs and have the potential to improve outcomes for people with cancer around the world.

Strategic partners to advance global development and commercialization activities:

  • Gilead and Arcus have a 10-year all-in partnership that included a significant capital investment and equity stake by Gilead into Arcus. Gilead holds co-development and co-commercialization rights to zimberelimab (anti-PD1 antibody) and an option to license current and future molecules.
  • Taiho has exercised option rights in Japan and other countries in Asia (excluding China) for the majority of Arcus’ clinical portfolio ̶  including domvanalimab, zimberelimab, etrumadenant, and AB308.

Clinical collaborations to explore novel combinations

Arcus is interested in clinical collaborations that evaluate novel combinations of Arcus molecules with other companies’ medicines or diagnostics to expand our understanding of important pathways and facilitate global access to expedite development and commercialization.

  • AstraZeneca and Arcus have a clinical collaboration on Pacific-8 a Phase III study evaluating our anti-TIGIT antibody domvanalimab plus durvalumab (Imfinzi®) for stage 3 non-small cell lung cancer with curative intent

Latest Press Releases

Featured Presentation

Latest Events